Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has signed and dated the informed consent.~* Patient has up to 2 documented stenotic or occluded atherosclerotic lesions (up ro 14 cm long) of the above-the-knee femoropopliteal artery, up to one in each limb, that meet all of the inclusion criteria and none of the exclusion criteria.~* Patient has a de novo or restenotic lesion(s) with \>50% stenosis documented angiographically and no prior stent in the target lesion.~* Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.~* Patient has a resting Ankle Brachial Index (ABI) \<0.9 or an abnormal exercise ABI if resting ABI is normal. Patient with incompressible arteries (ABI \>1.2) must have a Toe Brachial Index (TBI) \<0.8.~* Patient agrees to return for a clinical status assessment and duplex ultrasound at 6 months, 12 months, and at 2, 3, 4, and 5 years.~* Patient agrees to return for x-rays at 6 and 12 months.~* Patient agrees to return for angiography at 12 months.~* Patient agrees to be contacted by telephone at 1, 3, 9, and 18 months to assess clinical status.~Exclusion Criteria:~* Patient is pregnant or breast-feeding.~* Patient is simultaneously participating in another investigational drug or device study.~* Patient has significant stenosis or occlusion of inflow tract not successfully treated before this procedure.~* Patient has any planned surgical or interventional procedure within 30 days after the study procedure.~* Patient has had previous stenting of target vessel.~* Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated.~* Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, paclitaxel or nitinol and, in the opinion of the investigator, cannot be adequately premedicated.~* Patient lacks at least one patent vessel of runoff with \<50% stenosis throughout its course.~* Patient has untreated angiographically-evident thrombus in the target lesion.~\[Additional criteria may apply.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zilver® PTX™ Drug Eluting Vascular Stent
- 2 (Type: ACTIVE_COMPARATOR): Angioplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).